Comparative Pharmacology
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus TEGRETOL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus TEGRETOL XR.
OXCARBAZEPINE EXTENDED RELEASE TABLETS vs TEGRETOL-XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, inhibiting repetitive firing of action potentials, and reducing the propagation of synaptic impulses. Also modulates calcium channels and enhances potassium conductance.
Carbamazepine stabilizes inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission.
Initial: 300 mg orally twice daily. Increase by up to 600 mg/day at weekly intervals. Target maintenance: 1200-2400 mg/day in two divided doses. Extended-release tablets are dosed once daily: initial 600 mg, titrate weekly by 600 mg to maintenance 1200-2400 mg once daily.
200-400 mg orally twice daily; maximum 1200 mg/day for monotherapy, 1600 mg/day for combination therapy.
None Documented
None Documented
Oxcarbazepine: ~2 hours (not clinically relevant due to rapid conversion to MHD). MHD: ~9 hours (steady-state achieved in 2-3 days).
Initial: 25-65 hours; chronic dosing: 12-17 hours due to autoinduction. Steady-state reached in 2-4 weeks.
Renal: ~70% (mainly as glucuronide conjugates of MHD and oxcarbazepine, with <1% unchanged oxcarbazepine and ~27% unchanged MHD). Fecal: <1%.
Renal: ~72% as unchanged drug and metabolites (primarily glucuronides). Fecal: ~28% via bile (enterohepatic recirculation possible).
Category C
Category C
Anticonvulsant
Anticonvulsant